ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025

Financial Highlights - Oryzon Genomics reported a successful completion of a €30 million capital increase, oversubscribed from an initial €25 million target, with strong international demand [2][14] - The company secured a non-refundable EU grant of €13.26 million through the Med4Cure project, representing 64% of the total accepted budget for the project [15] - Research and development expenses for Q1 2025 were $2.6 million, consistent with the previous year, while general and administrative expenses increased to $1.2 million from $0.9 million [11][12] Clinical Development Updates - The company is finalizing preparations for the Phase III PORTICO-2 trial of vafidemstat for treating agitation and aggression in Borderline Personality Disorder (BPD), with a planned submission to the FDA in the first half of 2025 [2][8] - Oryzon continues patient recruitment for the ongoing EVOLUTION trial in schizophrenia, focusing on vafidemstat's efficacy in improving negative symptoms [4][24] - The Phase I/II trial of iadademstat in combination with immune checkpoint inhibitors for small cell lung cancer (SCLC) has begun patient recruitment, with the trial sponsored by the National Cancer Institute (NCI) [4][7] Research and Development Focus - Oryzon is exploring precision medicine trials for conditions like Fragile X syndrome and Phelan-McDermid syndrome, with potential IND submissions planned for 2025 [6][24] - The company is actively enrolling patients in the FRIDA trial, evaluating iadademstat in combination with gilteritinib for relapsed/refractory acute myeloid leukemia (AML) [16] - Oryzon's patent portfolio for vafidemstat has been strengthened with new patents related to treating ADHD and autism spectrum disorders, with protections extending until at least 2040 [8][24] Market Position and Strategy - Oryzon is positioned as a European leader in epigenetics, focusing on personalized medicine in CNS disorders and oncology [21] - The company has a robust clinical portfolio with two LSD1 inhibitors, vafidemstat and iadademstat, targeting significant unmet medical needs in various psychiatric and oncological conditions [21][22] - Oryzon's strategy includes leveraging collaborations with leading institutions and expanding clinical trials to enhance its market presence and therapeutic offerings [9][22]